| SELLAS Life Sciences Group, Inc.announced 19 Mar 2026 |
Enroll approximately 40 patients in the SLS009 clinical study in Europe |
Being checked30 Jun 2026 |
| SELLAS Life Sciences Group, Inc.announced 12 Nov 2025 |
Begin enrollment for an 80-patient trial in newly diagnosed AML patients |
Met31 Mar 2026 |
| SELLAS Life Sciences Group, Inc.announced 12 Aug 2025 |
Begin enrollment in the first-line AML trial for SLS009 |
Met31 Mar 2026 |
| SELLAS Life Sciences Group, Inc.announced 13 May 2025 |
Release full topline Phase 2 data of SLS009 |
Not met30 Jun 2025 |
| SELLAS Life Sciences Group, Inc.announced 13 May 2025 |
Reach 80 events in the Phase 3 REGAL trial |
Not met31 Dec 2025 |
| SELLAS Life Sciences Group, Inc.announced 28 Mar 2024 |
Report interim analysis of the Phase 1b/2 study of SLS009 in r/r PTCL |
Not met30 Jun 2024 |
| SELLAS Life Sciences Group, Inc.announced 8 Mar 2024 |
Report additional data from the Phase 2a SLS009 r/r AML trial |
Met30 Jun 2024 |
| SELLAS Life Sciences Group, Inc.announced 10 Aug 2023 |
Announce clinical activity for the lymphoma group |
Met30 Sep 2023 |
| SELLAS Life Sciences Group, Inc.announced 10 Aug 2023 |
Report additional immune response data for Phase 1 MPM study |
Met31 Dec 2023 |
| SELLAS Life Sciences Group, Inc.announced 10 Aug 2023 |
Report topline data for Phase 2a clinical trial of SLS009 |
Met31 Dec 2023 |
| SELLAS Life Sciences Group, Inc.announced 1 Jun 2023 |
Open the Phase 2a study for relapsed/refractory AML |
Met30 Jun 2023 |
| SELLAS Life Sciences Group, Inc.announced 1 Jun 2023 |
Report Phase 1 top line lymphoma data |
Met30 Sep 2023 |
| SELLAS Life Sciences Group, Inc.announced 1 Jun 2023 |
Complete interim analysis of the Phase 3 REGAL AML study |
Late31 Dec 2023 |
| SELLAS Life Sciences Group, Inc.announced 11 May 2023 |
Report topline data from the GPS investigator-sponsored trial in malignant pleural mesothelioma |
Met30 Jun 2023 |
| SELLAS Life Sciences Group, Inc.announced 16 Mar 2023 |
Initiate a Phase 2a clinical trial of GFH009 |
Met30 Jun 2023 |
| SELLAS Life Sciences Group, Inc.announced 16 Mar 2023 |
Report topline data for the Phase 2a GFH009 study |
Met31 Dec 2023 |
| SELLAS Life Sciences Group, Inc.announced 14 Nov 2022 |
Conduct final analysis of the REGAL clinical trial |
Not met31 Dec 2024 |
| SELLAS Life Sciences Group, Inc.announced 11 Aug 2022 |
Activate additional clinical trial sites in the United States, Europe, and Asia |
Met · disputed31 Dec 2022 |
| SELLAS Life Sciences Group, Inc.announced 12 May 2022 |
Report top-line results for the Phase 1/2 GPS study |
Met30 Jun 2022 |
| SELLAS Life Sciences Group, Inc.announced 12 May 2022 |
Complete final data analysis for the Phase 1/2 GPS study |
Met31 Dec 2022 |
| SELLAS Life Sciences Group, Inc.announced 6 Apr 2022 |
Complete the U.S. phase 1 trial for GFH009 |
Late31 Dec 2022 |
| SELLAS Life Sciences Group, Inc.announced 6 Apr 2022 |
Complete enrollment for the REGAL study |
Not met31 Mar 2023 |
| SELLAS Life Sciences Group, Inc.announced 12 Nov 2021 |
Conduct interim safety and futility analysis for the Phase 3 REGAL study |
Not met31 Dec 2022 |
| SELLAS Life Sciences Group, Inc.announced 14 Jan 2021 |
Report updated data from GPS combination studies in ovarian and malignant pleural mesothelioma |
Met30 Jun 2021 |